CHICAGO, Oct. 30, 2024 /PRNewswire/ -- Ambetter of Illinois (Ambetter), a product offered by Centene Corporation (NYSE: CNC), and managed locally by Meridian Health Plan of Illinois, Inc. (Meridian), announced today the addition of Advocate Health Care to its network, which will further increase members' access to quality healthcare in the Chicagoland area. Ambetter members can now receive care at any of Advocate's 11 hospitals and 300 sites of care in Illinois, with 6,500 physicians, and 11,000 nurses. Ambetter provides insurance through the Health Insurance Marketplace (Healthcare.gov).
"We are pleased to add Advocate Health Care to our network because it gives our Marketplace members access to their large network of primary care physicians and extensive specialties including cancer care, heart & vascular care, orthopedics, and women's health, among others," said Cristal Gary, Meridian Plan President and CEO. "Meridian is proud to provide quality and network support to Ambetter of Illinois."
Access to Advocate Health Care providers and its services is effective immediately to all Ambetter of Illinois members, and to those who enroll in its plans during Open Enrollment for the Health Insurance Marketplace for Illinois, which runs from November 1, 2024, through January 15, 2025. Existing and new Ambetter of Illinois' members can make an appointment, find a provider, or review their benefits by logging into their account at ambetterofillinois.com.
Ambetter of Illinois, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer a variety of affordable health insurance plans for Illinois residents in plan year 2025. Open Enrollment for the Health Insurance Marketplace for Illinois runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15 for coverage starting Jan. 1, 2025.
| Last Trade: | US$38.42 |
| Daily Change: | 0.78 2.07 |
| Daily Volume: | 12,429,664 |
| Market Cap: | US$18.870B |
July 29, 2025 July 25, 2025 April 25, 2025 February 24, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
